8th Floor, Detech II Building, 107 Nguyen Phong Sac, Cau Giay District - Hanoi City.
Dr Peter Sutherland (OAM)

Tiến sĩ Peter Sutherland được đào tạo tại Úc, Hoa Kỳ và Vương quốc Anh và từ đó đã có được hơn hai mươi lăm năm kinh nghiệm trong thực hành tiết niệu. Ông là Trưởng khoa Tiết niệu tại bệnh viện giảng dạy lớn nhất tại thành phố Adelaide, Hoàng gia Adelaide trong hai mươi năm. Với Khoa Phẫu thuật của Đại học Adelaide, ông quản lý một nhóm các nhà nghiên cứu cung cấp thử nghiệm các loại thuốc và kỹ thuật mới cho nhiều tình trạng tiết niệu.

Các lĩnh vực đặc biệt quan tâm của bác sĩ Sutherland là ung thư tuyến tiền liệt, điều trị bằng laser điều trị tắc nghẽn tuyến tiền liệt, bệnh thận và rối loạn cương dương.

Robot phẫu thuật

Bác sĩ Sutherland là công cụ lãnh đạo nhóm phẫu thuật đầu tiên giới thiệu phẫu thuật cắt bỏ tuyến tiền liệt triệt để bằng robot vào hệ thống y tế công cộng của Úc. Ông đã thực hiện hơn 2000 quy trình da Vinci trong khoảng thời gian 11 năm khiến ông trở thành một trong những bác sĩ phẫu thuật người máy giàu kinh nghiệm nhất ở Úc. Anh ta tiếp tục hoàn thành hơn 130 trường hợp mỗi năm và thông qua sự liên kết của anh ta với Bệnh viện Hoàng gia Adelaide, anh ta cung cấp một dịch vụ robot cho cả bệnh nhân công và tư nhân.

  • 1976: Graduated University of Adelaide Medical School – MBBS
  • 1977: FRACS
  • 1982: Fellowship in Urology
  • 1982: Fellowship in Urological Surgery

1985 – Present: Private practice in Adelaide, South Australia. Principal interests include Andrology and Prostate Disease. The practice has set up Australasia’s first private specialist day surgery managing only urological conditions.

2014: Senior Visiting Consultant in Urology at the Royal Adelaide Hospital, Adelaide.

1995 – April 2014: Head of the Urology Unit at the Royal Adelaide Hospital, Adelaide.

1989 – 1995: Senior Visiting Medical Specialist in Urology at the Royal Adelaide Hospital, Adelaide.

1985 – 1989: Visiting Medical Specialist in Urology at Flinders Medical Centre, Adelaide under the guidance of Professor Villis Marshall.

1984: Appoiinted: to UCLA Medical Centre as a Foreign Fellow under the guidance of Dr J Kauffmann, Chief of Urology. Again, the main focus of this appointment
was in the area of Andrology.

1983: Appointed to Institute of Urology, London as Clinical Assistant with Dean of the Institute, Mr John Pryor. This Fellowship was principally in the area of Andrology which was Mr Pryor’s main area of interest.

1982: Advanced Trainee (Urology), Flinders Medical Centre under the guidance of Professor Villis Marshall.

1980 – 1981: Advanced Trainee (Urology), Royal Adelaide Hospital under the guidance of Mr John Maddern, (Head of Unit 1980-1981).

1979: Appointed to Urological Training Post, Royal Adelaide Hospital

1977 – 1978: Basic Surgical Training, Royal Adelaide Hospital

1976: Internship Royal Adelaide Hospital

  • 1988: President of the Urological Society in South Australia.
  • 1987 – 1992: Appointed to the Australasian Board of Urology.
  • 1998 – present: Has acted as a National Advisory Board Member for:
    • Pfizer and Viagra, Pharmacia and Caverject, Abbott and Uprima, Eli Lilly and Cialis, AMS and their penile prosthetic devices, Bayer-GSK and Levitra, Astra Zeneca, Zoladex and Cosudex, Device Technology and the daVinci Robot, Eli Lilly
  • 2004: Principal Surgeon, Robotic Surgical Programme,
    Royal Adelaide Hospital.
  • 2005: Mentor surgeon, Robotic Surgical Programme,
    Royal Adelaide Hospital, Australia.
  • 2006: Mentor surgeon, Robotic Surgical Programme,
    St Vincent’s Hospital, Sydney, Australia.
  • 2007: Mentor surgeon, Robotic Surgical Programme,
    St Vincent’s Hospital, Sydney, Australia.
  • 2007: Mentor surgeon, Robotic Surgical Programme,
    Tauronga Hospital, New Zealand.
  • 2008: Mentor surgeon, Robotic Surgical Programme,
  • 2008: John of God Hospital, Perth, Australia.
  • 2008: Mentor surgeon, Robotic Surgical Programme,
  • 2008: Royal Adelaide Hospital, Australia.
  • 2008: Mentor surgeon, Greenslopes Private Hospital.
  • 2009: Mentor Surgeon, Greenslopes Private Hospital.
  • 2010: Mentor Surgeon, Wesley Hospital, Brisbane
  • 2011: Mentor Surgeon, East Kent Hospital, United Kingdom.
  • 2011: Mentor Surgeon, Cabrini Hospital, Melbourne.
  • 2011: Mentor Surgeon, St Vincent’s Hospital, Sydney.
  • 2012: Mentor Surgeon, Macquarie University Hospital,
    Hurstville Private Hospital, Sydney.
  • 2013: Mentor Surgeon, Sydney Adventist Hospital.
  • 2014: Mentor Surgeon, St Andrew’s Hospital, Adelaide.
  • 2014 – Present: ASERNIP-S advisory clinician
  • 2014 – Present: Emerging Technologies and Biostatistics.
  • South Australian Medical Board
  • Royal Australasian College of Surgeons
  • Urological Society of Australasia
  • Prostate Cancer Foundation of Australia
  • Australian Prostate Collaboration
  • International Society of Sexual Medicine
  • Societe Internationale d’Urologie
  • Society of Robotic Surgery – Charter Member
  1. Sutherland PD, Matson PL, Masters JR, Pryor JP. Association between infertility
    following reversal of vasectomy and the presence of sperm agglutinating activity in
    semen. Int J Androl. 1984;7:503-8.
  2. Sutherland PD, Maddern JP, Jose JS, Marshall VR. Urethral stricture after cardiac
    surgery.Br J Urol. 1983;55:413-6.
  3. Sutherland PD, Landon GV, Matson PL, Pryor JP. Round headed sperm. Br J
    Urol. 1985;57:486.
  4. Sutherland PD, Howard PR, Marshall VR. Colonic infarction following ethanol
    embolisation of the kidney. Br J Urol. 1986;58:337. Peter Sutherland
  5. Gallus A, Murphy W, Nacey J, Morris M, Sutherland P, Marshall V, Magnani H.
    The influence of Org 10172, and antithrombotic heparinoid, on urinary blood loss
    after transurethral prostatectomy. Thromb Res. 1989;56:229-38.
  6. Maddern GJ, Sutherland PD. Laparoscopic exploration for a presumed intraabdominal
    testicle.Endosc Surg Allied Technol. 1994; 2:293.
  7. Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD,
    Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ. Elevated levels of
    peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by
    radical prostatectomy for early-stage prostate cancer. Cancer Res. 1999 ;59:2324-8.
  8. Tooher R, Sutherland P, Costello A, Gilling P, Rees G, Maddern G. A systematic
    review of holmium laser prostatectomy for benign prostatic hyperplasia. J. Urol.
  9. McMahon CG, Stuckey BG, Lording DW, Wittert GA, Murphy A, Shin J,
    Sutherland PD,Palmer NR, Lowy MP, Jesudason DR, Fredlund P. A 6-month
    study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a
    randomised, double-blind, parallel-group, placebo-controlled study in Australian men.
    Int J Clin Pract. 2005;59:143-9.
  10. Borg M, Sutherland P, Stapleton A, Bolt J, Steele D, Landers B, Porter A,
    Buxton S, Heilbornn C, Wong HZ. Outcome of post-prostatectomy radiotherapy in
    one institution. Australas Radiol. 2006;50:475-80.
  11. Lowy M, Collins S, Bloch M, Gillman M, Lording D, Sutherland P, Wang H,
    Stecher V. Quality of erection questionnaire correlates: change in erection quality
    with erectile function,hardness, and psychosocial measures in men treated with
    sildenafil for erectile dysfunction. J Sex Med. 2007;4:83-92.
  12. Ludbrook G, Sutherland P. Erroneous pulse oximetry readings during robotic
    prostatectomy. Anaesth Intensive Care. 2007; 35:144-5.
  13. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM,
    Viktrup L. Effects of once-daily Tadalafil on erectile function in men with erectile
    dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. Eur
    Urol. 2009;56:727-35.
  14. Ricciardelli C, Bianco-Miotto T, Jindal S, Dodd TJ, Cohen PA, Marshall VR,
    Sutherland PD, Samaratunga H, Kench JG, Dong Y, Wang H, Clements JA,
    Risbridger GP, Sutherland RL, Tilley WD, Horsfall DJ; Australian Prostate
    Cancer BioResource. Comparative biomarker expression and RNA integrity in
    biospecimens derived from radical retropubic and robot-assisted laparoscopic
    prostatectomies. Cancer Epidemiol Biomarkers Prev., 2010, 19, 1755-1765.
  15. Centenera, M.; Gillis, J.; Hanson, A.; Jindal, S.; Taylor, R.; Risbridger, G.;
    Sutherland, P.; Scher, H.; Raj, G.; Knudsen, K.; Yeadon, T.; Tilley, W.; Butler, L.
    Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human
    prostate tumors. Clinical Cancer Research, 2012; 18(13):3562-3570 Peter Sutherland
  16. Selth LA; Townley, SL; Bert, AG; Stricker, PD; Sutherland, PD; Horvath, LG;
    Goodall, GJ; Butler, LM; Tilley, WD. Circulating microRNAs predict biochemical
    recurrence in prostate cancer patients. British Journal of Cancer, 2013; 109(3);641-
  17. Plagakis S, Foreman D, Sutherland P, Fuller A. Transperitoneal robot-assisted
    prostatectomy should be considered in prostate cancer patients with pelvic kidneys.
    Journal of Endourology Case Reports 2016; 2(1): 38-40 doi: 10.1089/cren.2016.0006
  18. Plagakis S, Neumann P, OCallaghan M, Foreman D, Fuller A, Sutherland P,
    Wells R. Age is not associated with continence outcomes after a robot assisted
    laparoscopic radical prostatectomy (RALP) Supportive Care in Cancer 2016; 24 (S1):
  19. Plagakis S, OCallaghan M, Neumann P, Fuller A, Wells R, Sutherland P,
    Foreman D. Age does not affect continence outcome after robot assisted
    laparoscopic prostatectomy (RALP). BJU International 2016; 118(S1): 20
  20. Neumann P, OCallaghan M, Foreman D, Plagakis S, Sutherland P, Fuller A,
    Wells R. Bladder neck displacement and continence outcomes within 12 months of
    robot assisted radical prostatectomy (RARP). BJU International 2016; 118(S1): 41
  21. Lin D, Plagakis S, Fuller A, Sutherland P, OCallaghan M, Neumann P, Foreman
    D. What affect does prostate volume have on continence after robotic prostatectomy?
    ANZ Journal of Continence 2016
en_AUEN viVI